Cost effectiveness of coronary heart disease prevention strategies in adults

PharmacoEconomics

Volumn 14, Issue 1, 1998, Pages 27-48

  Brown, Adalsteinn D ^a,b,c   Garber, Alan M ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Stamos Associates Inc   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT;

COST EFFECTIVENESS ANALYSIS; DYSLIPIDEMIA; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK MANAGEMENT; SMOKING CESSATION;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; ESTROGEN REPLACEMENT THERAPY; EXERCISE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; QUALITY OF LIFE; SMOKING CESSATION;

EID: 0031827735     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814010-00004     Document Type: Review

References (81)

1. Robinson JG, Leon AS. The prevention of cardiovascular disease: emphasis on secondary prevention. Med Clin North Am 1994; 78: 69-98
2. Oster G, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health 1986; 76: 647-56
3. Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York: Oxford University Press, 1993: 1-478
4. The Multiple Risk Factor Intervention Trial (MRFIT): a national study of primary prevention of coronary heart disease. JAMA 1976; 235: 825-7
5. Shea S, Cook EF, Kannel WB, et al. Treatment of hypertension and its effects on cardiovascular risk factors: data from the Framingham Heart Study. Circulation 1985; 71: 22-30
6. Kannel WB. Clinical misconceptions dispelled by epidemiological research. Circulation 1985; 92: 3350-60
7. Keys A, Aravanis C, Blackburn HW, et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Medica Scand Suppl 1966; 460: 1-392
8. Weinstein MC, Stason WB. Hypertension: a policy perspective. Cambridge (MA): Harvard University Press, 1976
9. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
10. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217-32
11. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732-9
12. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996; 82-134
13. McPherson K. International differences in medical care practices. In: Poullier JP, Schieber GJ, editors. Health care systems in transition: the search for efficiency. Paris: OECD, 1991: 17-28
14. Welch WP, Miller ME, Welch G, et al. Geographic variation in expenditures for physicians' services in the United States. N Engl J Med 1993; 328: 621-7
15. Garber AM, Fuchs VR, Silverman JF. Case mix costs, and outcomes: differences between faculty and community services in a university hospital. N Engl J Med 1984; 310: 1231-7
16. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease. Part I: general principles. Prog Cardiovasc Dis 1994; 37: 161-84
17. National Committee on Quality Assurance. Health plan employer data information set, 3.0, Washington, DC: National Committee on Quality Assurance, 1996
18. Oster G, Huse PM, Delea TE, et al. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA 1988; 256: 1315-8
19. Neil HAW, Roe L, Godlee RJP, et al. Randomized trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995; 310: 569-73
20. Altman DG, Flora JA, Fortman SD, et al. The cost-effectiveness of three smoking cessation programs. Am J Public Health 1987; 77: 162-5
21. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counselling smokers to quit. JAMA 1989; 261: 75-9
22. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22: 1697-702
23. Phillps CJ, Prowle MJ. Economics of a reduction in smoking: case study from Heartbeat Wales. J Epidemiol Community Health 1993; 47: 215-23
24. Green LW, Johnson KW. Health education and health promotion. In: Mechanic D, editor. Handbook of health, health care, and the health professions. New York: The Free Press, 1997: 744-60
25. Tsevat J. Impact and cost-effectiveness of smoking interventions. Am J Med 1992; 93: 435-75
26. Windsor RA, Warner KE, Cutter GR. A cost-effectiveness analysis of self-help smoking cessation methods for pregnant women. Public Health Rep 1988; 103: 83-7
27. Poullier JP, Schieber GJ, editors. Organization for Economic Cooperation and Development (OECD). Health care systems in transition: the search for efficiency. Paris: OECD, 1990
28. Scheetman G, Wolff N, Byrd JC, et al. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996; 11: 277-86
29. Hatziandreu EI, Koplan JP, Weinstein MC, et al. A cost effectiveness analysis of exercise as a health promotion activity. Am J Public Health 1988; 78: 1417-21
30. Jacoby DB. Letter. N Engl J Med 1986; 315: 399
31. Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus. Diabetes Care 1987; 10: 639-44
32. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
33. Daly E, Roche M, Barlow D, et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368-400
34. Tosteson ANA. Hormone replacement therapy: benefit, risk and cost considerations. J Clin Pharmacol 1994; 34: 719-22
35. Goddard M. The cost effectiveness of hormone replacement therapy: a review. York: Centre for Health Economics, University of York, 1990. Discussion paper no.: 73
36. Tosteson ANA, Rosenthal DI, Melton LJ, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densiometry and hormone replacement therapy. Ann Intern Med 1990: 113: 594-603
37. Lobo RA. Benefits and risk of estrogen replacement therapy. Am J Obstet Gynecol 1995; 173: 982-9
38. Delva MD. Hormone replacement therapy: risks, benefits, and costs. Can Fam Physician 1993; 39: 2149-54
39. Falkeborn M, Persson F, Apomamai HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynecol 1992; 99: 821-8
40. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983; 38: 445-55
41. Weinstein MC, Tosteson AN. Cost-effectiveness of hormone replacement. Ann NY Acad Sci 1990; 592: 162-72
42. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992; 156: 312-6
43. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237-8
44. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199-208
45. Lawrence WF, Fryback DG, Martin PA, et al. Health status and hypertension: a population based study. J Clin Epidemiol 1996; 49: 1239-45
46. Stevens RD, Bingley LJ, Boger M, et al. Variability in the management of hypertension and cost-effectiveness: methodology, community care results and potential cost. Soc Sci Med 1984; 296: 732-9
47. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990; 112: 192-202
48. Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 407-13
49. Johannesson M, Dahlof B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people: an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Inter Med 1993; 234: 317-23
50. Ramsay LE, Yeo WW, Jackson PR. Thiazide diuretics; first-line therapy for hypertension. J Hypertens 1992; 10: 529-33
51. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM study. Ann Intern Med 1991; 114: 613-20
52. Cantor JC, Morisky DE, Green LW, et al. Cost-effectiveness of educational interventions to improve patient outcomes in blood pressure control. Prev Med 1985; 14: 783-800
53. McNeil BJ, Varady PD, Burrows BA, et al. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease. N Engl J Med 1975; 293: 216-21
54. England WL, Grim CE, Weinberger MH, et al. Cost effectiveness in the detection of renal artery stenosis. J Gen Intern Med 1988; 3: 344-50
55. Nissinen A, Tuomilehto J, Kottke TE, et al. Cost-effectiveness of the North Karelia hypertension program. Med Care 1986; 24: 767-80
56. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-8
57. Hamilton VH, Racicot F-E, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 1995; 273: 1032-6
58. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124: 518-31
59. Pharoah PD, Sanderson SP. Health promotion in primary care: modelling the impact of intervention on coronary heart disease and stroke. J Public Health Med 1995; 17: 150-6
60. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51
61. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
62. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274-82
63. Garber AM, Littenberg B, Sox HC, et al. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med 1991; 151: 1089-95
64. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990; 263: 393-6
65. Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. JAMA 1987; 258: 2381-7
66. Avins AL, Browner WS. Lowering risk without lowering cholesterol: implications for national cholesterol policy. Ann Intern Med 1996; 125: 502-6
67. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988; 259: 2249-54
68. Martens LL, Rutten FFH, Erkelens DW, et al. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol 1990; 65: 27F-32F
69. Tosteson ANA, Weinstein MC, Hunink MGM, et al. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation 1997; 95: 24-30
70. Berwick DM, Cretin S, Keeler F. Cholesterol, children, and heart disease: an analysis of alternatives. Pediatrics 1981; 68: 721-30
71. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990; 264: 3025-33
72. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patient with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443-50
73. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 25-8
74. Pilote L, Granger C, Armstrong PW, et al. Differences in the treatment of myocardial infarction between the United States and Canada: a survey of physicians in the GUSTO trial. Med Care 1995; 33: 598-610
75. Darling GM, Johns JA, McCloud PI, et al. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595-601
76. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocystene as a risk factor for vascular disease: probable benefits of increasing folic acid. JAMA 1995; 274: 1049-57
77. Gustaffson C, Asplund K, Britton M, et al. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspectives. BMJ 1992; 305: 1457-60
78. Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol 1995; 75: 23B-6B
79. Aspirin to prevent heart attack or stroke. Drug Ther Bull 1994; 32: 1-3
80. Sox HC Jr, Littenberg B, Garber AM. The role of exercise testing in screening for coronary artery disease. Ann Intern Med 1989; 1110: 456-69
81. Weinstein MC. Economic assessment of medical practices and technologies. Med Decis Making 1981; 1: 309-30